Drug Profile
PASylated interferon alpha - XL-protein GmbH
Alternative Names: PAS-IFNα; xl-080Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator XL-protein GmbH
- Class Anti-infectives; Anti-inflammatories; Interferons
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Infections; Inflammation
Highest Development Phases
- No development reported Infections; Inflammation
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Infections in Germany
- 28 Sep 2020 No recent reports of development identified for preclinical development in Inflammation in Germany
- 09 Aug 2016 PASylated interferon alpha - XL-protein GmbH is available for licensing as of 09 Aug 2016. http://www.xl-protein.com/